Eva Lengfelder
Overview
Explore the profile of Eva Lengfelder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, et al.
Hemasphere
. 2023 Jul;
7(7):e904.
PMID: 37427146
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18-60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index...
2.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali H, et al.
Ann Hematol
. 2023 Jan;
102(3):547-561.
PMID: 36695874
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years...
3.
Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, et al.
Leukemia
. 2021 Nov;
35(12):3631.
PMID: 34785795
No abstract available.
4.
Hirt C, Hoster E, Unterhalt M, Hanel M, Prange-Krex G, Forstpointner R, et al.
Hemasphere
. 2021 Jun;
5(7):e600.
PMID: 34179697
The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety...
5.
Kayser S, Schlenk R, Lebon D, Carre M, Gotze K, Stolzel F, et al.
Haematologica
. 2021 May;
106(12):3100-3106.
PMID: 34047178
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after...
6.
Jann J, Streuer A, Hecht A, Nolte F, Nowak V, Danner J, et al.
Leuk Lymphoma
. 2020 Jul;
61(13):3066-3077.
PMID: 32723198
Although acute promyelocytic leukemia (APL) has evolved to the AML entity with the best prognosis, typical 'early death' (ED) events still account for mortality rates of ∼20% in population-based studies....
7.
Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, et al.
Leukemia
. 2020 Feb;
34(9):2333-2341.
PMID: 32076120
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median...
8.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al.
Lancet
. 2019 Dec;
394(10216):2271-2281.
PMID: 31868632
Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles...
9.
Sanz M, Fenaux P, Tallman M, Estey E, Lowenberg B, Naoe T, et al.
Blood
. 2019 Feb;
133(15):1630-1643.
PMID: 30803991
Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in...
10.
Braess J, Amler S, Kreuzer K, Spiekermann K, Lindemann H, Lengfelder E, et al.
Leukemia
. 2018 Oct;
32(12):2558-2571.
PMID: 30275528
Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd...